Anavex Life Sciences (AVXL) vs Outlook Therapeutics (OTLK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Outlook Therapeutics (OTLK) has outperformed Anavex Life Sciences (AVXL) over the past year, losing 51.3% versus a loss of 84.3%. Over five years, AVXL leads with a -91.5% price change compared with -98.6% for OTLK. Outlook Therapeutics is the larger company by market cap ($145.8 million vs $138.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVXL | OTLK |
|---|---|---|
| Share price | $1.49 | $0.5989 |
| Market cap | $138.12M | $145.80M |
| 1-day change | -3.25% | +6.19% |
| YTD return | -58.15% | -62.09% |
| 1-year return | -84.35% | -51.31% |
| 5-year return | -91.50% | -98.58% |
| EPS (TTM) | $-0.14 | $-0.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.50 | $2.54 |
| 52-week low | $1.44 | $0.161 |
| Distance from 52-week high | -84.32% | -76.40% |
| Analyst consensus | none | none |
| Avg. price target upside | — | +739.87% |
| Average volume | 983.35K | 13.43M |
| Shares outstanding | 92.70M | 243.45M |
| Employees | 34 | 17 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OTLK has outperformed AVXL by 33.0 percentage points over the past year.
- The two companies sit in different sectors: Anavex Life Sciences in Health Care and Outlook Therapeutics in Healthcare.
About Anavex Life Sciences
AVXL stock →Anavex Life Sciences Corp. operates as a biopharmaceutical company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 34 employees
About Outlook Therapeutics
OTLK stock →Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Healthcare · Biotechnology · 17 employees
AVXL vs OTLK FAQ
Which is bigger, Anavex Life Sciences or Outlook Therapeutics?
Outlook Therapeutics (OTLK) is larger, with a market capitalization of $145.80M compared with $138.12M for Anavex Life Sciences (AVXL).
Which stock has performed better over the past year, AVXL or OTLK?
OTLK returned -51.31% over the past 12 months, compared with -84.35% for AVXL (price return, excluding dividends). Past performance does not predict future results.
Are Anavex Life Sciences and Outlook Therapeutics in the same industry?
No. Anavex Life Sciences is in the Health Care sector, while Outlook Therapeutics is in Healthcare.